We are pleased to announce that Biotech Finances has featured RebrAIn in their recent article. RebrAIn has successfully completed a €3.7 million funding round led by Karista, with participation from Nouvelle Aquitaine Co-Investissement and existing investors.
Our CE-marked and FDA-cleared SaaS solution revolutionizes neurosurgical procedures by using advanced AI algorithms and MRI sequences to provide optimal targets for electrode placement in Deep Brain Stimulation (DBS) surgeries. The funds will support team expansion and international commercialization of our precision AI-driven neurosurgery solutions.
Read the article, in french, here.
An English translation by Google is available here.
